Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G with the United States Securities and Exchange Commission on November 7, 2024, indicating a change in their holdings of bluebird bio, Inc. The filing reveals that Goldman Sachs collectively has shared voting and dispositive power over 2,193,979 shares of bluebird bio, representing a 0.1% stake in the company. The document specifies that the shares are beneficially owned by certain operating units of Goldman Sachs and that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of bluebird bio. The filing includes various exhibits such as a joint filing agreement and powers of attorney, and it clarifies the organizational structure and authority within Goldman Sachs regarding the securities ownership.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G with the United States Securities and Exchange Commission on November 7, 2024, indicating a change in their holdings of bluebird bio, Inc. The filing reveals that Goldman Sachs collectively has shared voting and dispositive power over 2,193,979 shares of bluebird bio, representing a 0.1% stake in the company. The document specifies that the shares are beneficially owned by certain operating units of Goldman Sachs and that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of bluebird bio. The filing includes various exhibits such as a joint filing agreement and powers of attorney, and it clarifies the organizational structure and authority within Goldman Sachs regarding the securities ownership.